LEAP 2 Chronic EFS

Abbott

Status: Enrolling

Conditions: Bradycardia; Cardiac Rhythm Disorder; Cardiac Pacemaker

Treatments: Device: AVEIR CSP Leadless Pacemaker System

Study type: Interventional

Funder types: Industry

Identifiers

NCT07287423

ABT-CIP-10614

Details and patient eligibility

About

Prospective, single-arm, non-randomized, unblinded, chronic feasibility study designed to evaluate the safety and performance of the AVEIR™ Conduction System Pacing (CSP) Leadless Pacemaker system.

Full description

The purpose of this clinical investigation is to evaluate the chronic safety and performance of the AVEIR CSP Leadless Pacemaker system in a patient population with standard pacing indications.

Subjects participating in the study will have data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subject must have at least one standard pacemaker indication
2. Subject must be at least 18 years of age
3. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams
4. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, as approved by the local EC

Exclusion criteria

1. Subject has a mechanical tricuspid valve, percutaneous tricuspid valve repair or replacement, or an implanted vena cava filter
2. Subject has evidence of tricuspid stenosis, tricuspid atresia, or presence of any condition that precludes appropriate vascular access for the study procedure
3. Subject has previous myocardial infarction
4. Subject is expected to be pacemaker dependent
5. Subject has a previous or existing lead or device in the right heart or interventricular septum (includes lead fragments, temporary pacing leads, and closure devices)
6. Subject has an active implantable electronic device that cannot be turned off during the study procedure
7. Subject has recent cardiovascular or peripheral vascular surgery within 30 days of enrollment
8. Subject has known allergy or hypersensitivity to < 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material used in the study procedure
9. Subject is unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
10. Subject has known chronic renal insufficiency including patients on dialysis
11. Subject has an active systemic infection
12. Subject has known history or repair of an atrial septal defect, patent foramen ovale, or ventricular septal defect
13. Subject is currently participating in another clinical investigation that might impact the outcomes of the clinical investigation
14. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
15. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with the follow-up requirements of the clinical investigation
16. Subject is unable to read or write

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Treatment Arm

Experimental group

Treatment:

Device: AVEIR CSP Leadless Pacemaker System